Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology
Published in: Molecular Imaging and Biology 5/2010

01-10-2010 | Research Article

The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

Authors: Trond Velde Bogsrud, Dimitrios Karantanis, Mark A. Nathan, Brian P. Mullan, Gregory A. Wiseman, Jan L. Kasperbauer, Carl C. Reading, Trine Björo, Ian D. Hay, Val J. Lowe

Published in: Molecular Imaging and Biology | Issue 5/2010

Login to get access

Abstract

Purpose

To explore the prognostic value of 2-deoxy-2-[18F]fluoro-d-glucose (FDG) positron emission tomography (PET) in patients with suspected residual or recurrent medullary thyroid carcinoma (MTC).

Procedures

This retrospective study included all patients with MTC examined with FDG-PET at Mayo Clinic, Rochester, Minnesota, from October 1999 to March 2008. The PET results were compared with other imaging studies and clinical findings, including carcinoembryonic antigen and calcitonin levels.

Results

Twenty-nine patients with MTC were included. PET was positive in 14 patients, with follow-up information for 11; six died from metastatic disease, four had disease progression, and one remained in stable condition. PET was negative in 15 patients, with follow-up for 12; one had recurrent disease, and 11 had no evidence of clinical disease. Calcitonin doubling time was shorter for PET-positive than for PET-negative patients.

Conclusion

FDG-PET has high prognostic value in patients with suspected residual or recurrent MTC.
Literature
1.
You YN, Lakhani V, Wells SA, Moley JF (2006) Medullary thyroid cancer. Surg Oncol Clin N Am 15:639-660CrossRefPubMed
2.
Kebebew E, Ituarte PHG, Siperstein AE, Duh Q-Y, Clark OH (2000) Medullary thyroid carcinoma. Clinical characteristics, treatment, prognostic factors, and a comparison of staging system. Cancer 88:1139-1147CrossRefPubMed
3.
de Groot JWB, Kema IP, Breukelman H, van der Veer E, Wiggers T, Plukker JTM, Wolffenbuttel BHR, Links TP (2006) Biochemical markers in the follow-up of medullary thyroid cancer. Thyroid 16:1163-1170CrossRefPubMed
4.
Schlumberger M, Pacini F (2003) Medullary thyroid carcinoma. In: Schlumberger M, Pacini F, eds. Thyroid tumors. Paris: Nucleon, 305-335
5.
Hyer SL, Vini L, A´Hern R, Harmer C (2000) Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 26:686-690CrossRefPubMed
6.
Roman S, Lin R, Sosa JA (2006) Prognosis of medullary thyroid carcinoma. Demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 107:2134-2142CrossRefPubMed
7.
Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648CrossRefPubMed
8.
Barbet J, Campion L, Kraeber-Bodere F, Chatal JF (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling time in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084CrossRefPubMed
9.
Behr TM, Becker W (2005) Imaging of medullary thyroid cancer. In: Biersack HJ, Grünwald F (eds) Thyroid cancer, 2nd edn. Springer Verlag, Berlin, chapter 18:311-333 (ISBN-10 3-540-22309-6)
10.
Pellegriti G, Leboulleux S, Baudin E, Bellon N, Scollo C, Travagli J, Schlumberger M (2003) Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative imaging. Br J Cancer 88:1537-1542CrossRefPubMed
11.
Machens A, Schneyer U, Holzhausen H, Dralle H (2005) Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029-2034CrossRefPubMed
12.
Rohren EM, Turkington TG, Coleman RE (2004) Clinical Application of PET in Oncology. Radiology 231:305-332CrossRefPubMed
13.
Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496-507CrossRefPubMed
14.
Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE (2008) Impact of positron emission tomography / computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26:2155-22161CrossRefPubMed
15.
Hillner BE, Siegel BA, Shields AF, Liu D, Gareen IF, Hunt E, Coleman RE (2009) Relationship Between Cancer Type and Impact of PET and PET/CT on Intended Management: Findings of the National Oncologic PET Registry. J Nucl Med 49:1928-1935CrossRef
16.
Gillies RJ, Robey I, Gatenby RA (2008) Causes and Consequences of Increased Glucose Metabolism of Cancers. J Nucl Med 49 (Suppl 2):24S-42SCrossRefPubMed
17.
de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FGD-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786-794CrossRefPubMed
18.
Szakáll S, Ésik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, Ágoston P, Trón L (2002) 18F-FDG PET Detection of Lymph Node Metastases in Medullary Thyroid Carcinoma. J Nucl Med 43:66-71PubMed
19.
Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Körber C, Grünwald F (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study. Eur J Nucl Med 28:1671-1676CrossRefPubMed
20.
Giraudet AL, Vanel D, Leboulleux S, Aupérin A, Dromain C, Chami L, Tovo NN, Lumbroso J, Lassau N, Bonniaud G, Hartl D, Travagli J-P, Baudin E, Schlumberger M (2007) Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metabol 92:4185-4190CrossRef
21.
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F (2007) Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metabol 92:4590-4597CrossRefPubMed
22.
Yen TWF, Shapiro SE, Gagel RF, Sherman SI, Lee JE, Evans DB (2003) Medullary thyroid carcinoma: results of a standardized surgical approach in a contemporary series of 80 consecutive patients. Surgery 134:890-900CrossRefPubMed
23.
Ong SC, Schröder H, Patel SG, Tabangay-Lim IM, Doddamane I, Gönen M, Shaha AR, Tuttle RM, Shah JP, Larson SM (2007) Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels. J Nucl Med 48:501-507CrossRefPubMed
24.
Koopmans KP, de Groot JWB, Plukker JTM, de Vries EGE, Kema IP, Sluiter WJ, Jager PL, Links TP (2008) 18F-Dihydroxyphenylalanine PET in Patients with Bochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation. J Nucl Med 49:524-531CrossRefPubMed
25.
Giraudet AL, Ghulzan AA, Aupérin A, Leboulleux S, Chehboun A, Troalen F, Dromain C, Lumbroso J, Baudin E, Schlumberger (2008) Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239-246CrossRef
Metadata
Title
The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma
Authors
Trond Velde Bogsrud
Dimitrios Karantanis
Mark A. Nathan
Brian P. Mullan
Gregory A. Wiseman
Jan L. Kasperbauer
Carl C. Reading
Trine Björo
Ian D. Hay
Val J. Lowe
Publication date
01-10-2010
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 5/2010
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-009-0276-2

Other articles of this Issue 5/2010

Molecular Imaging and Biology 5/2010 Go to the issue

Research Article

A Study on the Prognostic Evaluation of Carbon Ion Radiotherapy for Head and Neck Adenocarcinoma with C-11 Methionine PET

TRIBUTE

In Memory of Senator Ted Stevens, 1923–2010, US Senator for the State of Alaska, 1968–2008

Research Article

18F-Labeled Galacto and PEGylated RGD Dimers for PET Imaging of αvβ3 Integrin Expression

Research Article

Synthesis and Optimization of the Labeling Procedure of 99mTc-Hynic-Interleukin-2 for In vivo Imaging of Activated T lymphocytes

Research Article

A Comparison Between Time Domain and Spectral Imaging Systems for Imaging Quantum Dots in Small Living Animals

Rapid Communication

AuNP-DG: Deoxyglucose-Labeled Gold Nanoparticles as X-ray Computed Tomography Contrast Agents for Cancer Imaging